Jakovljevic MM, Ogura S. Health economics at the crossroads of centuries - From the past to the future. Front Public Health. 2016;4:115.

Article  PubMed  Google Scholar 

Vijayasimha N. Pharma GCCs increasingly maximising multidisciplinary skills in bioinformatics, data sciences, etc. 2024 [cited 15 January 2025]. https://www.pharmabiz.com/NewsDetails.aspx?aid=171822&sid=1.

Viseven. HEOR in Pharma: what it is & why conduct it in 2024. 2023 [updated 6 June 2024; cited 25 September 2024]. https://viseven.com/heor-pharma/HEOR%20professionals%20help%20decision%2Dmakers,or%20defining%20the%20market%20cost.

Kahn JG, Mwai D, Kazi D, Marseille E. Health economics: tools to measure and maximize programme impact. In: Macfarlane S, AbouZahr C, editors. The Palgrave handbook of global health data methods for policy and practice. London: Palgrave Macmillan; 2019.

Google Scholar 

ISPOR. The future of HE+OR. ISPOR; 2020 [cited 3 September 2024]. https://www.ispor.org/docs/default-source/ispor-good-practices-for-outcomes-research-index/he-or_whitepaper_00120201130.pdf?sfvrsn=6a6587a4_0.

ISPOR. About HEOR. ISPOR [cited 3 September 2024]. https://www.ispor.org/heor-resources/about-heor.

Wang T, McAuslane N, Goettsch WG, Leufkens HGM, De Bruin ML. Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement. Int J Technol Assess Health Care. 2023;39(1): e20.

Article  PubMed  PubMed Central  Google Scholar 

van Nooten F, Holmstrom S, Green J, Wiklund I, Odeyemi IA, Wilcox TK. Health economics and outcomes research within drug development: challenges and opportunities for reimbursement and market access within biopharma research. Drug Discov Today. 2012;17(11–12):615–22.

Article  PubMed  Google Scholar 

Bungay KM, Sanchez LA. Types of economic and humanistic outcomes assessments. American College of Clinical Pharmacy; [cited 6 September 2024]. https://www.accp.com/docs/products/ppc11/pharmacoeconomics.pdf.

Tonin FS, Aznar-Lou I, Pontinha VM, Pontarolo R, Fernandez-Llimos F. Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions. Pharm Pract (Granada). 2021;19(1):2302.

Article  PubMed  PubMed Central  Google Scholar 

van Roijen L, Koopmanschap MA, Rutten FF, van der Maas PJ. Indirect costs of disease; an international comparison. Health Policy. 1995;33(1):15–29.

Article  PubMed  Google Scholar 

Research O. What is the role of PROMs in health economic evaluation? [cited 10 January 2025]. https://ous-research.no/home/healtheconomics/FAQ/23753.

Kim Y, Kim Y, Lee HJ, Lee S, Park SY, Oh SH, et al. The primary process and key concepts of economic evaluation in healthcare. J Prev Med Public Health. 2022;55(5):415–23.

Article  PubMed  PubMed Central  Google Scholar 

Drummond M, Sculpher M, Claxton K, Pammer L, Stoddart G, Torrance G, et al. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.

Google Scholar 

Rabarison KM, Bish CL, Massoudi MS, Giles WH. Economic evaluation enhances public health decision making. Front Public Health. 2015;3:164.

Article  PubMed  PubMed Central  Google Scholar 

Duthie T, Trueman P, Chancellor J, Diez L. Research into the use of health economics in decision making in the United Kingdom—phase II is health economics ‘for good or evil’? Health Policy. 1993;46:143–57.

Article  Google Scholar 

Adane E, Atnafu A, Aschalew AY. The cost of illness of hypertension and associated factors at the University of Gondar Comprehensive Specialized Hospital Northwest Ethiopia, 2018. Clinicoecon Outcomes Res. 2020;12:133–40.

Article  PubMed  PubMed Central  Google Scholar 

Zawudie AB, Lemma TD, Daka DW. Cost of hypertension illness and associated factors among patients attending hospitals in Southwest Shewa Zone, Oromia Regional State, Ethiopia. Clinicoecon Outcomes Res. 2020;12:201–11.

Article  PubMed  PubMed Central  Google Scholar 

Loesch GH, Cruz JAW, Gasparetto J, Oliveira DDS, Telles JP, Tuon FF. Cost minimization analysis of outpatient parenteral/oral antibiotic therapy at a trauma hospital: Public health system. Infect Control Hosp Epidemiol. 2021;42(12):1445–50.

Article  PubMed  Google Scholar 

Chuang FR, Lee CH, Chang HW, Lee CN, Chen TC, Chuang CH, et al. A quality and cost-benefit analysis of dialyzer reuse in hemodialysis patients. Ren Fail. 2008;30(5):521–6.

Article  PubMed  Google Scholar 

Hofmarcher T, Borg S. Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden. J Med Econ. 2015;18(7):492–501.

Article  PubMed  Google Scholar 

Lim EA, Sohn HS, Lee H, Choi SE. Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea. Cost Eff Resour Alloc. 2014;12:19.

Article  PubMed  PubMed Central  Google Scholar 

Fortney JC, Maciejewski ML, Tripathi SP, Deen TL, Pyne JM. A budget impact analysis of telemedicine-based collaborative care for depression. Med Care. 2011;49(9):872–80.

Article  PubMed  Google Scholar 

Sciences NCfAT. Clinical outcome—toolkit. U.S. Department of Health and Human Services [cited 4 September 2024]. https://toolkit.ncats.nih.gov/glossary/clinical-outcome/.

Alshammari TM. Drug safety: the concept, inception and its importance in patients’ health. Saudi Pharm J. 2016;24(4):405–12.

Article  PubMed  Google Scholar 

Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763–74.

Article  PubMed  PubMed Central  Google Scholar 

Barry HE, Hughes CM. Economical, clinical, and humanistic outcomes and pharmaceutical care. In: Alves da Costa F, van Mil J, Alvarez-Risco A, editors. The pharmacist guide to implementing pharmaceutical care. Cham: Springer; 2019.

Google Scholar 

Deng ZJ, Gui L, Chen J, Peng SS, Ding YF, Wei AH. Clinical, economic and humanistic outcomes of medication therapy management services: a systematic review and meta-analysis. Front Pharmacol. 2023;14:1143444.

Article  PubMed  PubMed Central  Google Scholar 

Topachevskyi O. What do you need to know about health economics and outcomes research (HEOR) in Pharma. Digital Health Outcomes; 2023 [cited 3 September 2024]. https://digitalho.com/blog/heor/.

Holtorf AP, Brixner D, Bellows B, Keskinaslan A, Dye J, Oderda G. Current and future use of HEOR data in healthcare decision-making in the United States and in emerging markets. Am Health Drug Benefits. 2012;5(7):428–38.

PubMed  PubMed Central  Google Scholar 

Marella RK, Koppaka V, Thakkar A, Raina H. The power of RWE in HEOR for healthcare optimization. India; 2023.

Panahiazar M, Taslimitehrani V, Pereira NL, Pathak J. Using EHRs for heart failure therapy recommendation using multidimensional patient similarity analytics. Stud Health Technol Inform. 2015;210:369–73.

PubMed  PubMed Central  Google Scholar 

Fang HSA, Tan NC, Tan WY, Oei RW, Lee ML, Hsu W. Patient similarity analytics for explainable clinical risk prediction. BMC Med Inform Decis Mak. 2021;21(1):207.

Article  PubMed  PubMed Central  Google Scholar 

Miller P. Role of pharmacoeconomic analysis in R&D decision making: when, where, how? Pharmacoeconomics. 2005;23(1):1–12.

Article  PubMed  Google Scholar 

Petykó ZI, Kaló Z, Espin J, Podrazilová K, Tesař T, Maniadakis N, et al. Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings. Cost Eff Resour Alloc. 2021;19(1):57.

Article  PubMed  PubMed Central  Google Scholar 

Maurer M, Mangrum R, Hilliard-Boone T, Amolegbe A, Carman KL, Forsythe L, et al. Understanding the influence and impact of stakeholder engagement in patient-centered outcomes research: a qualitative study. J Gen Intern Med. 2022;37(Suppl 1):6–13.

Article  PubMed  PubMed Central  Google Scholar 

Guidance for industry. patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:79.

Article  Google Scholar 

Schmitt A. Understanding the significance of health economics and outcomes research (HEOR) in medicines development. 2024 [cited 16 September 2024]. https://gmdpacademy.org/news/understanding-the-significance-of-health-economics-and-outcomes-research-heor-in-medicines-development/.

Mitchell JM, Patterson JA. The inclusion of economic endpoints as outcomes in clinical trials reported to ClinicalTrials.gov. J Manag Care Spec Pharm. 2020;26(4):386–93.

PubMed  Google Scholar 

Nuijten M, Van Wilder P. The impact of early phase price agreements on prices of orphan drugs. BMC Health Serv Res. 2021;21(1):222.

Article  PubMed  PubMed Central  Google Scholar 

Amin P, Nam S, Perez L, Smith J. Integrated evidence generation: a paradigm shift in biopharma. 2021 [cited 09 April 2025]. https://www.mckinsey.com/industries/life-sciences/ourinsights/integrated-evidence-generation-a-paradigm-shift-in-biopharma.

Grutters JPC, Govers T, Nijboer J, Tummers M, van der Wilt GJ, Rovers MM. Problems and promises of health technologies: the role of early health economic modeling. Int J Health Policy Manag. 2019;8(10):575–82.

Article  PubMed  PubMed Central